Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.
Many new treatments for pediatric skin conditions have been either approved or have recently released new data. Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics and vice-chair of the Department of Dermatology at University of California San Diego School of Medicine, both in California, described these updates at the Fall Clinical Dermatology conference held October 21 to 24 in Las Vegas, Nevada.1
For atopic dermatitis (AD), Eichenfield described updates to the current pipeline.
The topical treatments mentioned were:
He briefly mentioned the status of systemic JAK inhibitors for pediatric patients—abrocitinib (PF-04965842; Pfizer), baricitinib (Olumiant; Eli Lilly and Company), and upadacitinib (Rinvoq; AbbVie)—of which abrocitinib and upadacitinib for adolescents is currently on hold for approval from the FDA for the treatment of AD, and baricitinib not yet filed.3
Eichenfield next tackled pediatric psoriasis, describing the newest treatments, such as:
He presented a study4 that compared pediatric patients treated with methotrexate vs biologic agents. There were 234 patients with moderate to severe psoriasis treated with at least 3 months of either methotrexate or biologic. It was found that 71.4% of patients treated with biologics compared to 40% of methotrexate patients achieved Psoriasis Area and Severity Index (PASI)75. Also, the biologic medications had a longer drug survival than its comparator. This demonstrates the efficacy difference between treatments, according to Eichenfield.
Switching gears, he discussed pediatric specific COVID-19 skin symptoms.
COVID-19 skin symptoms, Eichenfield continued, are different in pediatric patients compared to adults. He explained that symptoms are usually milder in adults, with infants and the immunocompromised at a greater risk of becoming more ill from the virus. He gathered data from several studies,5-7 that found the skin symptoms to include multiple rashes (extensive or localized) such as hives, petechial, psoriasiform, maculopapular, papulovesicular (varicella-like), livedoid, and mucositis. There may also be signs of Kawasaki-disease or vasculitis in pediatric patients.
Next, Eichenfield pondered on whether COVID toes was in relation to infection or an immune response?
The toes often show pernio-like lesions, according to Eichenfield, but there is usually no history of Raynaud’s syndrome or autoimmune disease. In some cases, skin biopsies reveal immunohistochemistry positive for COVID-19 in the tissue and both polymerase chain reaction (PCR) tests and serology were commonly negative. Other articles state that the lesions are not associated with COVID-19.8-11
With COVID-19 research still underway, dermatology practices have completely changed in how they function, Eichenfield explained. With teledermatolgy, it has changed the way the patient and physician interact for both good and bad.
Eichenfield concluded his presentation, stating that in the future there will be new genome targeted interventions for genetic diseases and evolved therapies in inflammatory skin disorders.
Eichenfield is an investigator or consultant for AbbVie, Almirall, Arcutis Biotherapeutics, Aslan, Dermavant Sciences, Dermira, Inc., Forte Biosciences, Galderma Laboratories, Ichnos Sciences, Incyte Corporation, Eli Lilly and Company, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Ortho Dermatology, and Verrica Pharmaceuticals.
1. Eichenfield L. Pediatric dermatology update. Presented at: Fall Clinical Dermatology Conference 2021; October 21 to October 24, 2021; Las Vegas, Nevada, and virtual.
2. Clinical trial of fb-401 for the treatment of atopic dermatitis fails to meet statistical significance. Published September 9, 2021. Accessed October 18, 2021. https://www.fortebiorx.com/investor-relations/news/news-details/2021/Clinical-Trial-of-FB-401-For-the-Treatment-of-Atopic-Dermatitis-Fails-to-Meet-Statistical-Significance/default.aspx
3. FDA requiring black box warning for certain jak inhibitors. Dermatology Times. September 2, 2021. Accessed October 19, 2021. https://www.dermatologytimes.com/view/fda-requiring-black-box-warning-for-certain-jak-inhibitors
4. Bronckers IMGJ, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384-392. doi:10.1001/jamadermatol.2019.4835
5. Casas CG, Català A, Hernández GC, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. British Journal of Dermatology. 2020;183(1):71-77. doi:10.1111/bjd.19163
6. Cordoro KM, Reynolds SD, Wattier R, McCalmont TH. Clustered cases of acral perniosis: Clinical features, histopathology, and relationship to COVID-19. Pediatric Dermatology. 2020;37(3):419-423. doi:10.1111/pde.14227
7. Hernandez C, Bruckner AL. Focus on “covid toes.” JAMA Dermatol. 2020;156(9):1003. doi:10.1001/jamadermatol.2020.2062
8. Colmenero I, Santonja C, Alonso-Riaño M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven pediatric cases. Br J Dermatol. 2020;183(4):729-737. doi:10.1111/bjd.19327
9. Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486-492. doi:10.1016/j.jaad.2020.05.109
10. Herman A, Peeters C, Verroken A, et al. Evaluation of chilblains as a manifestation of the covid-19 pandemic. JAMA Dermatol. 2020;156(9):998-1003. doi:10.1001/jamadermatol.2020.2368
11. McCleskey PE, Zimmerman B, Lieberman A, et al. Epidemiologic analysis of chilblains cohorts before and during the covid-19 pandemic. JAMA Dermatol. 2021;157(8):947-953. doi:10.1001/jamadermatol.2021.2120